ADMA Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	509.86	510.17	426.45	258.22	154.08	80.94
Revenue Growth (YoY)	10.99%	19.63%	65.16%	67.58%	90.36%	91.72%
Cost of Revenue	197.45	217.41	206.9	169.27	118.82	79.77
Gross Profit	312.42	292.77	219.55	88.94	35.27	1.17
Selling, General & Admin	94.24	91.58	74.12	59.02	52.46	42.9
Depreciation & Amortization Expenses	0.18	0.14	0.39	0.72	0.72	0.72
Research & Development	6.53	4.76	1.81	3.3	3.61	3.65
Other Operating Expenses	12.59	4.84	4.25	4.27	17.84	12.29
Total Operating Expenses	113.54	101.32	80.57	67.31	74.63	59.55
Operating Income	214.84	191.44	138.98	21.63	-39.37	-58.37
Interest Income	2.36	1.87	2.1	1.62	0.05	0.04
Interest Expense	-7.24	-7.11	-13.93	-25.03	-19.28	-13.06
Other Non-Operating Income (Expense)	-12.12	-12.34	-14.71	-76.33	-33.84	-13.53
Total Non-Operating Income (Expense)	-17	-17.57	-26.54	-99.74	-53.08	-26.55
Pretax Income	206.33	182.66	125.71	-28.24	-65.9	-84.92
Provision for Income Taxes	40.98	35.73	-71.96	-	-	-
Net Income	165.35	146.93	197.67	-28.24	-65.9	-84.92
Net Income to Common	165.35	146.93	197.67	-28.24	-65.9	-71.65
Net Income Growth	-20.03%	-25.67%	-	-	-	-
Shares Outstanding (Basic)	239	238	233	224	198	140
Shares Outstanding (Diluted)	244	245	243	224	198	140
Shares Change (YoY)	-0.05%	0.64%	8.65%	13.19%	41.77%	62.03%
EPS (Basic)	0.69	0.62	0.85	-0.13	-0.33	-0.51
EPS (Diluted)	0.68	0.60	0.81	-0.13	-0.33	-0.51
EPS Growth	-20.00%	-25.93%	-	-	-	-
Free Cash Flow	107.9	27.82	110.45	4.03	-73.42	-125.88
Free Cash Flow Growth	287.85%	-74.81%	2641.28%	-	-	-
Free Cash Flow Per Share	0.44	0.11	0.45	0.02	-0.37	-0.90
Gross Margin	61.27%	57.39%	51.48%	34.44%	22.89%	1.45%
Operating Margin	42.14%	37.53%	32.59%	8.38%	-25.55%	-72.12%
Profit Margin	32.43%	28.80%	46.35%	-10.94%	-42.77%	-104.92%
FCF Margin	21.16%	5.45%	25.90%	1.56%	-47.65%	-155.52%
EBITDA	222.8	199.54	147.03	29.96	-32.25	-52.88
EBITDA Margin	43.70%	39.11%	34.48%	11.60%	-20.93%	-65.33%
EBIT	214.84	191.44	138.98	21.63	-39.37	-58.37
EBIT Margin	42.14%	37.53%	32.59%	8.38%	-25.55%	-72.12%
Effective Tax Rate	19.86%	19.56%	-57.24%	0.00%	0.00%	0.00%

SEC Filings: 10-K · 10-Q